Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pentapiperium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 0.57 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentapiperium SCHEMBL1222217 | 0.92 | CHRM3 (0.66) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Pentapiperium SCHEMBL454024 | 0.91 | CHRM3 (0.64) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL14237580 | 0.77 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Pentapiperide SCHEMBL25997 | 0.76 | MEN1 (0.51) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL2730650 | 0.74 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Iodide SCHEMBL3987354 | 0.72 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1222305 | 0.71 | CHRM2 (0.64) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4964029 | 0.70 | KMT2A (0.70) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL2990935 | 0.68 | CHRM3 (0.67) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tematropium SCHEMBL667952 | 0.67 | CHRM2 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553445-B1 | Composition for blocking light and method of forming an image using the composition | ROHM & HAAS ELECT MAT (US) | 2018-11-14 | — | — | EP | claimed |
| US-20170066727-A1 | Photostabilizing Compounds and Methods of Making and Using the Same | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2017-03-09 | — | — | US | claimed |
| WO-2017003685-A1 | PHOTOSTABILIZING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2017-01-05 | — | — | WO | claimed |
| EP-2950144-B1 | IMAGING PROCESS ON SUBSTRATES WITH AQUEOUS ALKALINE SOLUBLE UV BLOCKING COMPOSITIONS AND AQUEOUS SOLUBLE UV TRANSPARENT FILMS | ROHM & HAAS ELECT MAT (US) | 2016-12-14 | — | — | EP | claimed |
| CN-105319853-A | IMAGING ON SUBSTRATES WITH AQUEOUS ALKALINE SOLUBLE UV BLOCKING COMPOSITIONS AND AQUEOUS SOLUBLE UV TRANSPARENT FILMS | ROHM & HAAS ELECT MAT | 2016-02-10 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2010129316-A2 | COSMETIC COMPOSITIONS COMPRISING CYANODIPHENYLACRYLATES AND FILM FORMING POLYMERS | ELC MANAGEMENT LLC (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100040566-A1 | EMULSION | RIEMANN TRADING APS | 2010-02-18 | — | — | US | claimed |
| EP-2066286-A1 | EMULSION | Riemann Trading ApS (DK) | 2009-06-10 | — | — | EP | claimed |
| WO-2009016046-A2 | SUNLESS TANNING COMPOSITIONS COMPRISING SUBSTITUTED POLYAMINE COMPOUNDS | BASF SE (CH) | 2009-02-05 | — | — | WO | claimed |
| WO-2008034447-A1 | EMULSION | RIEMANN TRADING APS (DK) | 2008-03-27 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0895026-B1 | Method to control deflagration while extinguishing a combustion flame | SOUDURE AUTOGENE FRANCAISE (FR) | 2002-05-15 | — | — | EP | claimed |
| EP-0721382-B1 | METHOD, DEVICE AND APPARATUS FOR COATING A TUBE, PARTICULARLY A PIPELINE TUBE | ISOTUB COATING (FR) | 1999-09-22 | — | — | EP | claimed |
| EP-0895026-A1 | Apparatus and method to control deflagration while extinguishing a combustion flame | LA SOUDURE AUTOGENE FRANCAISE (FR) | 1999-02-03 | — | — | EP | claimed |
| EP-0721382-A1 | METHOD, DEVICE AND APPARATUS FOR COATING A TUBE, PARTICULARLY A PIPELINE TUBE | ISOTUB COATING (FR) | 1996-07-17 | — | — | EP | claimed |
| WO-1996003222-A1 | METHOD, DEVICE AND APPARATUS FOR COATING A TUBE, PARTICULARLY A PIPELINE TUBE | ISOTUB COATING (FR) | 1996-02-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066727-A1 | Photostabilizing Compounds and Methods of Making and Using the Same | SQLE, NQO1, TYR | CHRM3 4725/4885CHRM1 4710/4885CHRM2 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.